Serum Golgi protein 73 and glypican-3: early diagnostic biomarkers for hepatocellular carcinoma | ||||
| Kasr Al Ainy Medical Journal | ||||
| Volume 27, Issue 3, August 2022 PDF (259.97 K) | ||||
| DOI: 10.4103/kamj.kamj_24_19 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Doaa F. Gad; Islam Eid Mohamed; Essam Elmahdi; Abdelnaser A. Badawy; Gamal Othman; Mohamed G. Dawoud; Mohammed Diasty; Maysaa E. Zaki; Mohamed M. Abd El-Mawgod | ||||
| Abstract | ||||
| Objectives The prognosis of hepatocellular carcinoma (HCC) is extremely worse, and chronic hepatitis C virus infection is one of the most important causes of HCC. The use of diagnostic serological markers in following up the high-risk individuals for developing HCC may help in its early detection and therapy. This study aimed to assess the effectiveness of serum Golgi protein 73 (GP73) and glypican-3 (GPC3) as new tumor biomarkers for early detection of HCC. Patients and methods A case–control study included 125 patients infected with hepatitis C virus, comprising 60 with cirrhosis and 65 with HCC, in addition to 60 healthy individuals considered as the normal control group. Serum levels of GP73, GPC3, and alpha-fetoprotein (AFP) were assessed by enzyme-linked immunosorbent assay technique. Result Serum GP73 and AFP levels were significantly higher in patients with HCC as compared with cirrhosis and control groups; however, their levels were significantly increased in patients with cirrhosis as compared with the healthy group (both <0.001). However, GP73 was more sensitive than AFP in the diagnosis of HCC as the area under the receiver operating characteristic curve (area under the curve) with 95% confidence interval was 0.98 (0.95–1.0) for GP73 and 0.82 (0.74–0.90) for AFP. However, the area under the curve with 95% confidence interval for GPC3 was 0.44 (0.36–0.53). There was a significant association between AFP level and Barcelona clinic liver cancer staging of HCC (=0.02). In addition, the serum level of GPC3 was higher in cirrhotic patients than other groups (=0.007). Conclusion Serum GP73 and not GPC3 can be used as early potential tumor biomarker for HCC diagnosis and also to differentiate HCC from cirrhosis. | ||||
| Keywords | ||||
| alpha-fetoprotein; Cirrhosis; Glypican-3; Golgi protein 73; Hepatocellular carcinoma; Hepatitis C virus | ||||
|
Statistics Article View: 8 PDF Download: 7 |
||||
